ClinicalTrials.gg
Not yet recruitingNCT07390578Updated May 22, 2026

Upneeq vs. Lumify Ptosis

A Phase 4 interventional study of Oxymetazoline 0.1% (Upneeq) and Brimonidine 0.025% (Lumify) in Acquired Ptosis, sponsored by Duke University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Duke University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare the short-term effect of oxymetazoline 0.1% (Upneeq) versus brimonidine 0.025% (Lumify) on upper-eyelid position in adults with acquired ptosis. Participants will undergo standardized eyelid photography, receive a single dose of either Upneeq or Lumify in randomized order, and have repeat photographs approximately 60 minutes later. They will return for a second visit to receive the alternate medication using the same procedures. Eyelid height measurements will be obtained from coded images by masked graders. Data will be analyzed using paired statistical methods appropriate for a crossover design. Both medications are FDA-approved topical ophthalmic drops, and the study involves minimal risk with anticipated transient ocular irritation as the most common adverse event.

02

Conditions studied

  • Acquired Ptosis

Browse trials for

Keywords

  • Ptosis
  • Oxymetazoline
  • Brimonidine
03

In context

Blepharoptosis

76 studies on the registry are indexed under Blepharoptosis; 15 are open to participants now.

This study's planned enrollment of 50 is close to the median of 50 across 57 interventional studies indexed under Blepharoptosis.

Browse Blepharoptosis studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 273 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults age ≥18 years
  • Acquired ptosis with MRD1 ≤ 2.5 mm in at least one eye
  • Ability to complete both study visits (≥48 hours apart)
  • Fluent in English
  • Able to provide

Exclusion criteria

Exclusion Criteria:

  • Congenital ptosis or mechanical ptosis due to mass effect
  • Ocular surgery within the past 6 months
  • Significant active ocular surface disease
  • Current contact lens wear on study days
  • Known allergy to oxymetazoline or brimonidine
  • Use of MAO inhibitors, α-blockers, or medications
  • Pregnancy or lactation
  • Significant uncontrolled cardiovascular disease
  • Any condition that may interfere with study procedures or data reliability
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Upneeq First, then Lumify

    Participants receive oxymetazoline 0.1% (Upneeq) at Visit 1 and brimonidine 0.025% (Lumify) at Visit 2.

    Drug: Oxymetazoline 0.1% (Upneeq) · Drug: Brimonidine 0.025% (Lumify)

  • Experimental
    Lumify First, then Upneeq

    Participants receive brimonidine 0.025% (Lumify) at Visit 1 and oxymetazoline 0.1% (Upneeq) at Visit 2.

    Drug: Oxymetazoline 0.1% (Upneeq) · Drug: Brimonidine 0.025% (Lumify)

Interventions

06

What researchers measure

Primary outcomes

  1. Change in upper-eyelid height (MRD1) (Upneeq vs. Lumify)

    Change in MRD1 at \~60 minutes after drop instillation (Upneeq vs. Lumify)

    Time frame: 60 minutes after instillation

Secondary outcomes

  1. Change in palpebral fissure height (PFH)

    Time frame: 60 minutes after instillation

  2. Number of participants with Conjunctival redness

    Time frame: 60 minutes after each medication

  3. Participant-reported improvement in eyelid elevation or visual function

    Participants will report eyelid elevation and visual function on a 0-10 numeric rating scale after each medication, where: 0 = no noticeable eyelid lift and 10 = maximal eyelid lift. For visual function: 0 = no improvement in vision and 10 = maximal improvement in vision.

    Time frame: 60 minutes after each medication

  4. Frequency of Adverse Events

    Assess the safety and tolerability of a single dose of Upneeq and Lumify.

    Time frame: 60 minutes after each medication

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Aug 2027, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 5, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Dec 1, 2027
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07390578
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Feb 5, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
May 22, 2026

Study contacts

Christopher Dermarkarian
principal investigator · Duke University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Oxymetazoline · Brimonidine

Start the discussion